# Jan Kasper

> Jan Kasper is a seed investor at AceON Accelerator backing Biotechnology. See 12 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [AceON Accelerator](https://shizune.co/investors/profile/aceon-accelerator)
- Location: Bratislava, Slovakia (Slovak Republic)
- Total investments: 12
- Last investment: Jan 2026
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/dipl-ing-j%C3%A1n-kasper-phd-mba-phd-508703255

Jan Kasper is a seed investor at AceON Accelerator in Bratislava focused on Biotechnology and Artificial Intelligence. Ján Kasper is the Co-Founder of AceON Accelerator. Jan Kasper attended Slovak Technical University in Bratislava.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 33% |
| Artificial Intelligence | 4 | 33% |
| SaaS | 2 | 17% |
| Biopharma | 2 | 17% |
| Pharmaceutical | 2 | 17% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 6 | 50% |
| Pre-Seed | 4 | 33% |
| Funding Round | 1 | 8% |
| Venture - Series Unknown | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 4 | 33% |
| Austria | 1 | 8% |
| Germany | 1 | 8% |
| Portugal | 1 | 8% |
| Czech Republic | 1 | 8% |

6 countries tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| DeepSeq.AI | DeepSeq.AI was founded in 2019, with the overall mission of decoding the relationship between protein sequences and functions by combining wet-lab, software, and AI in a continuous development loop in order to design and screen novel protein drugs more efficiently. Up to date, DeepSeq.AI has developed a unique next-generation sequencing (NGS) basedAI platform to help pharma companies design novel protein drugs with high speed and accuracy.In 2021, DeepSeq.AI started to work with one of the top-10 global biopharma on feasibility studies to accelerate their drug discovery efforts. Those collaborations were successful, and we presented one of our successful projects at the Protein Engineering Summit Boston (PEGS) in May 2023, along with a number of other top biopharma and technology companies (e.g., Pfizer, Amgen, IBM). In Nov 2023, DeepSeq.AI was funded by UC Berkeley SkyDeck Fund and Merck Digital Sciences Studio (MDSS). |  | Venture - Series Unknown | Jan 07, 2026 |  |
| SentiVue | SentiVue is an advanced AI-driven platform tailored for dynamic businesses, transforming every customer touchpoint into a strategic asset for enhancing customer-brand loyalty, driving personalized experiences, and catalyzing sustainable growth without missing a beat. | $42.3K | Pre-Seed | Dec 06, 2024 |  |
| ExoMatter | ExoMatter is a digital materials development startup. They employ artificial intelligence algorithms to find better and more sustainable materials for their application. Their customized platform contains all material data in one location. They use scientific data on materials to develop enhanced and environmentally friendly materials. Theirmaterials research platform generates a customized list of materials for each client's application. |  | Pre-Seed | Oct 24, 2024 |  |
| ExoMatter | ExoMatter is a digital materials development startup. They employ artificial intelligence algorithms to find better and more sustainable materials for their application. Their customized platform contains all material data in one location. They use scientific data on materials to develop enhanced and environmentally friendly materials. Theirmaterials research platform generates a customized list of materials for each client's application. | $1.8M | Seed | Oct 24, 2024 |  |
| Lime Therapeutics | Lime Therapeutics aims to eliminate a variety of cancers by pursuing a novel approach targeting lipid metabolism. Cancers need lipids (often at high levels) in order to survive; thus finding drugs that can deprive cancers of lipids represents an attractive therapeutic strategy. However, technological barriers have prevented high-throughput drugdiscovery in this area. |  | Seed | Apr 08, 2024 |  |
| Eigen Therapeutics | Eigen Therapeutics is a biotechnology company on a mission to make therapies that make cancer easier to find and eliminate. Eigen is focused on the development of “priming” therapies, therapies that help targeted therapies reach their full potential by addressing cancer heterogeneity, making cancer cells more vulnerable and/or making healthycells more resilient to treatment. Eigen is building a high-throughput discovery platform to explore the space of priming therapies, leveraging proprietary machine learning algorithms to discover novel associations, new classes of drugs, and new potential therapies that change a cell's state to make it more vulnerable to a targeted therapy. The Eigen platform represents the intersection of biology and engineering, and includes robotic systems, laboratory operations software, and machine learning analysis pipelines—all developed in-house—with the ultimate goal of saving more lives. |  | Seed | Mar 11, 2024 |  |
| KiraGen Bio | KiraGen Bio is leveraging AI-driven, combinatorial gene editing to unlock the full potential of CAR-T cells against solid tumors. |  | Pre-Seed | Nov 27, 2023 |  |
| SharpGrid | SharpGrid is a data and technology business that is redefining on-trade and hospitality market research. To create an accurate and full picture of the on-trade channel, we collect data from all on-trade outlets (restaurants, bars, pubs, or cafés) on the market. SharpGrid's data-driven technologies help companies like Coca-Cola, Heineken, andMakro achieve commercial efficiency and growth. | $1.8M | Seed | Sep 11, 2023 |  |
| ExcepGen | ExcepGen is a venture-backed, early stage biotechnology company located in San Francisco. The company is focused on solving fundamental underlying problems in drug discovery and applying those solutions to create a new generation of therapeutics. | $4M | Seed | Aug 24, 2023 |  |
| tripmakery | tripmakery.com is an easy to use webapp that helps users to book group-accomodations all over Europe. With an database of 60.000 group hotels, tripmakery.com is the leading platform for larger group bookings. No matter whether 10 people travel together to Berlin or 50 people to Barcelona, tripmakery.com is the first platform to automate large groupbookings. Founded in 2015 by Robert Sasse and Ajmal Said in Vienna, tripmakery.com is backed by VC's like Speedinvest or Push Ventures and by the founders of 'hotel.de' one of the largest hotel-bookings platform in Germany. |  |  | Jul 20, 2023 |  |

10 of 12 investments shown.

## Co-investors
- [212 NexT](https://shizune.co/investors/profile/212-next) — VC Fund, 3 deals together
- [Bayern Kapital](https://shizune.co/investors/profile/bayern-kapital) — VC Fund, 2 deals together
- [Bloomhaus Ventures](https://shizune.co/investors/profile/bloomhaus-ventures) — VC Fund, 2 deals together
- [Illumina Ventures](https://shizune.co/investors/profile/illumina-ventures) — VC Fund, 2 deals together
- [2048 Ventures](https://shizune.co/investors/profile/2048-ventures) — VC Fund, 1 deal together
- [Allston Venture Fund](https://shizune.co/investors/profile/allston) — VC Fund, 1 deal together

## About AceON Accelerator

VC Fund · Prague, Czech Republic

AceON Accelerator elevates early-stage start-ups, providing the necessary know-how and investment opportunities to promising founders. And created by entrepreneurs and start-up enthusiasts from advisory & BPO company Accace, together with ZAKA VC fund, their accelerator program is designed to turn entrepreneurs' ideas into successfulbusinesses.

2 contacts available at AceON Accelerator.

| Name | Title | Profile |
| --- | --- | --- |
| Jan Kasper | Co-Founder | https://shizune.co/investors/profile/jan-kasper-29a1 |
| Peter Pašek | Co-Founder | https://shizune.co/investors/profile/peter-pa%C5%A1ek |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Jan Kasper invest in?

Jan Kasper invests primarily in Biotechnology, Artificial Intelligence and SaaS startups, most often at Seed and Pre-Seed stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Jan Kasper last invest?

The most recent investment recorded for Jan Kasper closed in Jan 2026. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co